📄

APOE deficiency inhibits amyloid-facilitated (A) tau pathology (T) and neurodegeneration (N), halting progressive ATN pathology in a preclinical model.

active
paper Created: By: unknown Quality: 50% ✓ SciDEX ID: paper-40307424
📄 Paper Details
APOE deficiency inhibits amyloid-facilitated (A) tau pathology (T) and neurodegeneration (N), halting progressive ATN pathology in a preclinical model.
["Vanherle S", "Janssen A", "Guti\u00e9rrez de Rav\u00e9 M", "Janssen B", "Lodder C", "Botella Lucena P", "Kessels S", "Hardy J", "Vandeput E", "Wang Y"]
Molecular psychiatry PubMed DOI
Abstract

In AD, amyloid pathology (A) precedes progressive development of tau pathology (T) and neurodegeneration (N), with the latter (T/N) processes associated with symptom progression. Recent anti-amyloid beta (Aβ) clinical trials raise hope but indicate the need for multi-targeted therapies, to effectively halt clinical AD and ATN pathology progression. APOE-related putative protective mutations (including APOE3Christchurch, RELN-COLBOS) were recently identified in case reports with exceptionally hig...

Metadata
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
5%
Debates
0
Incoming
1
Outgoing
1
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.